Assessing a heterogeneous disease like RA can be a challenge
Regular quantitative assessment of RA is key to improving patient outcomes.
- Regular, precise assessments of RA disease activity — as recommended by EULAR and ACR — are key to achieving specific target levels of disease activity and improving patient outcomes.1-7
Clinical assessments cannot always identify underlying disease activity or risk of future structural damage.8-10
- Physician and patient assessments of clinical symptoms can differ.8
- CRP and ESR do not always agree with physician assessment.9
- Structural damage can continue even when signs and symptoms appear to be controlled.10
No single biomarker adequately reflects the diverse biology driving RA.
- RA is a disease that involves complex interactions between multiple proteins in a number of tissues, including bone, cartilage, and synovium.11
- A multi-biomarker index can capture numerous biological pathways implicated in RA, with the potential to complement existing assessment tools and improve patient care.12